Preclinical studies have demonstrated that circulating RANKL is sufficient to induce concomitant bone resorption and muscle wasting, and that RANKL blockade attenuates both bone loss and cachexia in tumor-bearing mice [106]. The gene discussed is TNFSF11; the disease is neoplasm.